Background and Aims Lenvatinib is an effective drug in advanced HCC. Its combination with
the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor …

Background and Aims Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have
displayed an impressive objective response rate. This study aimed to clarify the mechanism …

Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint
inhibitor (ICI), nivolumab, are used for anticancer therapies against advanced hepatocellular …

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor
microenvironments may contribute to antitumor activity when combined with programmed …

Introduction While sorafenib monotherapy represented the mainstay of medical treatment for
advanced hepatocellular carcinoma (HCC) patients for more than a decade, novel agents …

China has one of the highest incidence rates of hepatocellular carcinoma (HCC) in the
world. As most patients are diagnosed with advanced or unretractable HCC, systematic …

Abstract Background and Aims: Combining anti-angiogenic therapy with immune checkpoint
blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for …

Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed
cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte …

Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for
hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the …

Background LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and
KIT. PEMBRO is an anti-PD-1 monoclonal antibody. LEN monotherapy is approved for first …